MicroRNA-19a functions as an oncogenic microRNA in non-small cell lung cancer by targeting the suppressor of cytokine signaling 1 and mediating STAT3 activation

International Journal of Molecular Medicine

Volumn 35, Issue 3, 2015, Pages 839-846

  Wang, Xuguang ^a   Chen, Zhe ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

MicroRNA 19a; Non small cell lung cancer; Suppressor of cytokine signaling 1; Tumor therapy; Tumorigenesis

Indexed keywords

MICRORNA; MICRORNA 19A; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MESSENGER RNA; MIRN19 MICRORNA, HUMAN; SOCS1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

3' UNTRANSLATED REGION; A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BINDING SITE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME;

3' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICRORNAS; RNA INTERFERENCE; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921794197     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2071     Document Type: Article

References (51)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Claassens L, van Meerbeeck J, Coens C, et al: Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 29: 2104-2120, 2011.
3. Hu Z, Chen X, Zhao Y, et al: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28: 1721-1726, 2010.
4. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
5. Blumenschein GR Jr and Herbst RS: Integration of targeted therapies in gemcitabine chemotherapy regimens. Clin Lung Cancer 4: 217-223, 2003.
6. Cabebe E and Wakelee H: Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 8: 15-27, 2007.
7. Ranganathan K and Sivasankar V: MicroRNAs - Biology and clinical applications. J Oral Maxillofac Pathol 18: 229-234, 2014.
8. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
9. Winter J, Jung S, Keller S, Gregory RI and Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11: 228-234, 2009.
10. Rottiers V, Najafi-Shoushtari SH, Kristo F, et al: MicroRNAs in metabolism and metabolic diseases. Cold Spring Harb Symp Quant Biol 76: 225-233, 2011.
11. Aigner A: MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J Mol Med (Berl) 89: 445-457, 2011.
12. Zimmerman AL and Wu S: MicroRNAs, cancer and cancer stem cells. Cancer Lett 300: 10-19, 2011.
13. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
14. Wang P, Chen L, Zhang J, et al: Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 33: 514-524, 2014.
15. Oh JS, Kim JJ, Byun JY and Kim IA: Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys 76: 5-8, 2010.
16. Wang P, Zhuang L, Zhang J, et al: The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol 7: 334-345, 2013.
17. Petrocca F, Visone R, Onelli MR, et al : E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13: 272-286, 2008.
18. Wu Q, Yang Z, An Y, et al: MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis 5: e1144, 2014.
19. Xu XM, Wang XB, Chen MM, et al: MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett 322: 148-158, 2012.
20. Yu G, Li H, Wang X, et al: MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion. Mol Cell Biochem 380: 239-247, 2013.
21. Lin Q, Chen T, Lin Q, Lin G, et al: Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol 107: 767-771, 2013.
22. Yu H and Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004.
23. Tian M, Wan Y, Tang J, et al: Depletion of tissue factor suppresses hepatic metastasis and tumor growth in colorectal cancer via the downregulation of MMPs and the induction of autophagy and apoptosis. Cancer Biol Ther 12: 896-907, 2011.
24. Zhang J, Li H, Yu JP, Wang SE and Ren XB: Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer 130: 1971-1980, 2012.
25. Huang C, Li H, Wu W, Jiang T and Qiu Z: Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1. Oncol Rep 30: 1223-1230, 2013.
26. Cittadini A, Monti MG, Iaccarino G, et al: SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway. Cardiovasc Res 96: 381-390, 2012.
27. Liu L, Li W, Wei X, et al: Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma. Gene Ther 20: 84-92, 2013.
28. Xu XL, Jiang YH, Feng JG, et al: MicroRNA-17, microRNA-18a, and microRNA-19a are prognostic indicators in esophageal squamous cell carcinoma. Ann Thorac Surg 97: 1037-1045, 2014.
29. Sochor M, Basova P, Pesta M, et al: Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer 14: 448, 2014.
30. Navarro A, Marrades RM, Vinolas N, et al: MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology 76: 162-169, 2009.
31. Chen Q, Xia HW, Ge XJ, et al: Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev 14: 7421-7426, 2013.
32. Murphy BL, Obad S, Bihannic L, et al : Silencing of the miR-17-92 cluster family inhibits medulloblastoma progression. Cancer Res 73: 7068-7078, 2013.
33. Li X, Xie W, Xie C, et al : Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation. Phytother Res 28: 1553-1560, 2014.
34. Wu TY, Zhang TH, Qu LM, et al: MiR-19a is correlated with prognosis and apoptosis of laryngeal squamous cell carcinoma by regulating TIMP-2 expression. Int J Clin Exp Pathol 7: 56-63, 2013.
35. Wang F, Li T, Zhang B, et al: MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 434: 688-694, 2013.
36. Krebs DL and Hilton DJ: SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19: 378-387, 2001.
37. Yasukawa H, Sasaki A and Yoshimura A: Negative regulation of cytokine signaling pathways. Annu Rev Immunol 18: 143-164, 2000.
38. He Y, Zhang W, Zhang R, Zhang H and Min W: SOCS1 inhibits tumor necrosis factor-induced activation of ASK1-JNK inflammatory signaling by mediating ASK1 degradation. J Biol Chem 281: 5559-5566, 2006.
39. Hanada T, Yoshida H, Kato S, et al: Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 19: 437-450, 2003.
40. Chinen T, Kobayashi T, Ogata H, et al: Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNgamma and IL-4 are involved. Gastroenterology 130: 373-388, 2006.
41. Sasi W, Sharma AK and Mokbel K: The role of suppressors of cytokine signalling in human neoplasms. Mol Biol Int 2014: 630797, 2014.
42. Chu PY, Yeh CM, Hsu NC, et al: Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma. Swiss Med Wkly 140: w13065, 2010.
43. Neuwirt H, Puhr M, Santer FR, et al: Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol 174: 1921-1930, 2009.
44. Komazaki T, Nagai H, Emi M, et al: Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol 34: 191-194, 2004.
45. Lesinski GB, Zimmerer JM, Kreiner M, et al: Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer 10: 142, 2010.
46. Zitzmann K, Brand S, De Toni EN, et al: SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 67: 5025-5032, 2007.
47. Zhao M, Gao FH, Wang JY, et al : JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 73: 366-374, 2011.
48. Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809, 2009.
49. Souma Y, Nishida T, Serada S, et al: Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells. Int J Cancer 131: 1287-1296, 2012.
50. Xu Y, Xu X, Gao X, Chen H and Geng L: Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2/STAT3 pathway. Int Immunopharmacol 19: 327-333, 2014.
51. Shimada K, Serada S, Fujimoto M, et al: Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells. Cancer Sci 104: 1483-1491, 2013.